ScheBo Biotech and M2-PK



A packed audience at Focus heard Ivor Smith of ScheBo Biotech present asummary of "Faecal Tumor M2-PK – an improvement in colorectal cancer detection" during Snippets @ Focus 2010. Many were probably surprised to learn that published studies already include over 10,000 people in total, demonstrating an average sensitivity of c.80% (much higher than guaiac FOBT!) and specificity in excess of 90% for colorectal cancer at acut-off of 4U/mL. The test is an ELISA and only needs awalnut-sized stool sample from asingle stool passage, without restrictions on diet or medication, which makes it convenient for "patients".

A DVD of the lecture is available on request from ScheBo Biotech, for those who didn't make it toFocus 2010 or whose timetable was too busy to attend the talk.